Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €17.25 EUR
Change Today +0.02 / 0.12%
Volume 83.8K
AB On Other Exchanges
Symbol
Exchange
EN Paris
OTC US
As of 11:35 AM 05/29/15 All times are local (Market data is delayed by at least 15 minutes).

ab science sa (AB) Snapshot

Open
€17.26
Previous Close
€17.23
Day High
€17.39
Day Low
€17.06
52 Week High
02/10/15 - €18.93
52 Week Low
10/16/14 - €7.16
Market Cap
576.5M
Average Volume 10 Days
121.4K
EPS TTM
€-0.49
Shares Outstanding
33.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AB SCIENCE SA (AB)

Related News

No related news articles were found.

ab science sa (AB) Related Businessweek News

No Related Businessweek News Found

ab science sa (AB) Details

AB Science S.A., a pharmaceutical company, engages in the discovery, development, and commercialization of protein kinase inhibitors for use in human and veterinary medicines. The company markets Masitinib for the treatment of oncology and inflammatory diseases for dogs and cats. It markets its Masitinib under the Masivet brand name in Europe; and Kinavet brand name in the United States. The company is also developing Masitinib in human indications that are in various Phase II and Phase III clinical trials for the treatment of oncology, inflammatory, hematology, and central nervous system diseases, as well as for the treatment of indolent systemic mastocytosis, non controlled severe asthma, refractory rheumatoid arthritis, progressive forms of multiple sclerosis, amyothrophic lateral sclerosis, and Alzheimer's diseases. It serves hospitals and specialist physicians. AB Science S.A. was founded in 2001 and is headquartered in Paris, France.

121 Employees
Last Reported Date: 04/30/15
Founded in 2001

ab science sa (AB) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: €456.7K
Compensation as of Fiscal Year 2013.

ab science sa (AB) Key Developments

AB Science SA Announces its Phase 2 with Masitinib in Relapsed or Refractory Peripheral T-Cell Lymphoma and Accelerate into Phase 3 Randomized Controlled Trial

AB Science SA announced that its phase 2 with masitinib in relapsed or refractory peripheral T-cell lymphoma (PTCL) was accelerated into a phase 3 randomized controlled trial. This phase 2-3 study is a prospective, multicenter, open-label, three-parallel groups, randomized trial to evaluate the efficacy and safety of masitinib plus dexamethasone with or without gemcitabine, as compared against the active control of dexamethasone plus gemcitabine, in patients with relapsed or refractory peripheral T-cell lymphoma. The primary endpoint of this study is overall survival. The clinical development program of masitinib in peripheral T-cell lymphoma started with a phase 2, open-label, three-parallel groups, randomized study, which involved the planned recruitment of 45 patients. Health authorities from 14 countries agreed to transform the phase 2 study directly into phase 3, with prospective recruitment of 270 patients. The decision to accelerate the phase 2 into phase 3 was based on the observation of a survival benefit with masitinib as compared to control (data blinded to sponsor and investigator) and acceptable safety with validation of the passage into phase 3 by the independent Data Monitoring Safety Board. Response to treatment of canine T-cell-multicentric lymphoma is classically described as poor, especially for pleomorphic and lymphoblastic forms, with median survival times of less than 8 months in most studies focusing on the interest of conventional chemotherapy. Two promising cases were reported in dogs with T-cell lymphoma treated with masitinib. Two female dogs were presented for T-cell lymphoma. Both dogs had been previously treated with glucocorticoids. The first dog also initially received vincristin (as part of a CHOP based protocol), but treatment was poorly tolerated. The second dog received one initial administration of L-asparaginase. Both dogs then received masitinib after this initial period. In the 2 dogs, masitinib was well tolerated. Progressive complete remission was reached in the first dog. The animal was still alive with complete remission and a good tolerance of masitinib for maintenance after more than 16 months of follow-up. Rapid complete remission was reached in the second dog. The animal was still alive with complete remission and a good tolerance of masitinib for maintenance after more than 8 months of follow-up.

AB Science S.A. - Special Call

To discuss on masitinib in the treatment of amyotrophic lateral sclerosis (ALS) with key opinion leaders from this disease, the current positioning of masitinib in ALS, the scientific rationale for developing masitinib in ALS, the efficacy and safety update on the on-going phase 3 study and the market potential for masitinib in ALS

AB Science S.A. Announces the Publication of Results from the First Randomized Phase 3 Study of Masitinib in Treatment of Advanced Pancreatic Ductal Adenocarcinoma

AB Science S.A. announced the publication of results from the first randomized phase 3 study of masitinib in treatment of advanced pancreatic ductal adenocarcinoma (PDAC). In patients with over-expression of ACOX1 in blood, administration of masitinib in combination with Gemzar produced a statistically significant overall survival advantage of +6.1 months (Hazard Ratio=0.23[0.10;0.51]) when compared with placebo administered in combination with Gemzar. In the pain subgroup, administration of masitinib in combination with Gemzar produced a statistically significant overall survival advantage of +2.6 months (Hazard Ratio=0.62[0.43;0.89]) when compared with placebo administered in combination with Gemzar. Safety of the combination remained acceptable with no overall detrimental effect on quality of life. A new confirmatory phase 3 trial of masitinib in advanced pancreatic cancer has been initiated, with an objective to replicate these promising results in a prospective manner.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AB:FP €17.25 EUR +0.02

AB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AB.
View Industry Companies
 

Industry Analysis

AB

Industry Average

Valuation AB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 238.5x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 221.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AB SCIENCE SA, please visit www.ab-science.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.